A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.

ABSTRACT:

Background

Currently, there are no direct comparisons of apixaban and rivaroxaban, two new oral direct factor Xa inhibitors approved for management of thromboembolic disorders.

Objective

Compare the pharmacokinetics and anti-factor Xa activity (AXA) of apixaban and rivaroxaban.

Methods

In this randomized, open-label, two-period, two-treatment crossover study, healthy subjects (N=14) received apixaban 2.5 mg twice daily (BID) and rivaroxaban 10 mg once daily (QD) for 4 days with a ≥4.5-day washout. Plasma samples were obtained for pharmacokinetic and AXA assessments; parameters were calculated using noncompartmental methods.

Results

Median time-to-maximum concentration was 2 hours for both compounds, and the mean half-life was 8.7 and 7.9 hours for apixaban and

SUBMITTER: Frost C 

PROVIDER: S-EPMC4235474 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature